Sign In
20 Dec 2010 07:00
For immediate release | 20 December 2010 |
ABCAM PLC
("Abcam" or "the Company")
Pre-Close Trading Update
Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces the following pre-close trading update ahead of its results for the six months ending 31 December 2010.
The Board is pleased to report that trading since the statement made at the Company's Annual General Meeting in November has continued in line with our expectations.
The business has performed well, notably in our largest geographic market, North America, whilst sales growth in the UK has been somewhat restrained owing to uncertainty caused by the recent UK Government spending review. Our effective cost control processes have ensured that margins remain strong.
The challenges to Governments in the West in addressing fiscal deficits, and the possible impact on publicly funded research projects, continue to merit a degree of caution, but the Board remains confident in the outlook for the full year.
The Company will report its interim results for the six months ending 31 December 2010 in the week commencing 7 March 2011.
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer | |
Jeff Iliffe, Chief Financial Officer www.abcamplc.com | |
Numis Securities | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Adviser | |
James Black - Corporate Broking | |
Buchanan Communications | + 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies and related products, headquartered in Cambridge, United Kingdom, with US offices in Cambridge, Massachusetts, and San Francisco, California, and Far East offices in Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All products are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 68,000 products, most of which are antibodies, from over 250 suppliers and employs 295 staff.
Follow the stocks
